Glucosa Braun

Glucosa Braun is an injectable solution containing glucose monohydrate as the active ingredient, supplied in a sterile aqueous form for intravenous administration. Marketed in the European Union as a prescription product, it provides a readily available source of carbohydrate for patients requiring parenteral nutrition, fluid replacement, or rapid correction of low blood glucose. The preparation is classified as an excipient used in clinical settings.

Glucosa Braun is indicated for clinical situations where an immediate carbohydrate source or fluid replacement is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to eat. - Support of fluid and electrolyte balance during surgery or critical illness. - Provision of energy in intravenous therapy for burn or trauma patients. - Adjunct in electrolyte replacement solutions to maintain plasma osmolarity.

Glucosa Braun may be associated with transient physiological changes following intravenous infusion, most of which are mild and resolve without intervention.

Common: - Mild hyperglycemia that normalizes as glucose is metabolized. - Temporary increase in serum sodium due to solution osmolarity. - Local irritation or mild pain at the infusion site. - Slight elevation of serum triglycerides in patients receiving large volumes. - Transient rise in blood lactate levels that normalize quickly. - Mild headache reported during rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Electrolyte imbalance such as hyponatremia or hyperkalemia. - Allergic reactions ranging from urticaria to anaphylaxis. - Volume overload causing pulmonary edema in susceptible individuals.

When prescribing Glucosa Braun, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks associated with intravenous carbohydrate administration.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Evaluate renal and cardiac function to avoid volume overload. - Use caution in patients with uncontrolled diabetes mellitus. - Monitor serum electrolytes, especially sodium and potassium, during therapy. - Avoid rapid bolus administration in neonates and infants. - Consider potential interactions with insulin or other hypoglycemic agents. - Document infusion site and observe for signs of phlebitis.

Glucosa Braun may affect the pharmacodynamics of other intravenously administered agents; awareness of potential interactions helps ensure safe co‑administration.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring. - Simultaneous infusion of hypertonic saline solutions that could exacerbate hypernatremia. - Mixing with calcium‑containing solutions that may precipitate. - Infusion with potassium‑rich solutions without monitoring serum potassium. - Concurrent use with sodium bicarbonate that could increase solution alkalinity.

Use with caution: - Concurrent use of diuretics that alter electrolyte balance. - Administration alongside catecholamines, which can increase glucose utilization. - Overlapping therapy with other carbohydrate‑containing parenteral solutions. - Co‑administration with glucocorticoids that may raise blood glucose levels.